Educational Symposium
Treatment of Anemia of CKD: What Is the Role of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors?
October 25, 2024 | 12:45 PM - 01:45 PM
Location: Marriott Grand Ballroom 8, Marriott Marquis
Session Description
Anemia is a common complication in patients with advanced CKD (both non-dialysis and on dialysis) that, untreated, is associated with decreased quality of life as well as increased morbidity and mortality. In the late 1980s, the availability of erythropoiesis-stimulating agents (ESAs) transformed anemia management in patients with CKD on dialysis, many of whom were dependent on transfusions up to that point. Injectable ESAs (along with iron repletion) remain the standard therapy for anemia of CKD to this day, with only modest advances since their introduction.However, in 2023, the first in a new class of agents – the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) – was approved in the United States for anemia of CKD in dialysis patients; a second agent was approved in early 2024. This new class of agents is the first oral treatment for anemia of CKD. As they become more widely available, it is important for clinicians to be aware of the advantages and potential disadvantages of these agents compared to ESAs. In this symposium, speakers discuss the science behind the development of these medications and the evolving role of these agents in clinical practice.
Support is provided by an educational grant from Akebia Therapeutics, Inc.
Learning Objective(s)
- Describe the mechanisms of action for HIF-PHIs
- Compare the safety profiles of ESAs and HIF-PHIs
- Describe important clinical factors in choosing between an ESA and a HIF-PHI
Learning Pathway(s)
- Dialysis
- Pharmacology
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- The Science behind HIF-PHI Development: From Bench to Clinical Trials
12:55 PM - 01:15 PM
- Incorporating HIF-PHIs into Clinical Practice
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM